Medtronic (NYSE:MDT) Stock Rating Upgraded by Wall Street Zen

by · The Cerbat Gem

Medtronic (NYSE:MDT – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Several other brokerages have also recently weighed in on MDT. Morgan Stanley restated an “overweight” rating and issued a $107.00 price target (up previously from $98.00) on shares of Medtronic in a research report on Tuesday, July 15th. Truist Financial boosted their target price on shares of Medtronic from $92.00 to $96.00 and gave the stock a “hold” rating in a report on Thursday, August 21st. William Blair upgraded shares of Medtronic to a “hold” rating in a research report on Friday, July 11th. BTIG Research reaffirmed a “neutral” rating on shares of Medtronic in a report on Friday, July 11th. Finally, Mizuho boosted their price objective on Medtronic from $98.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 16th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $102.14.

View Our Latest Research Report on MDT

Medtronic Trading Up 0.8%

Shares of MDT stock opened at $92.72 on Friday. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $118.93 billion, a price-to-earnings ratio of 25.54, a price-to-earnings-growth ratio of 2.36 and a beta of 0.77. Medtronic has a 12-month low of $79.29 and a 12-month high of $96.25. The stock’s 50-day moving average price is $90.31 and its 200-day moving average price is $88.02.

Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.03. The business had revenue of $8.58 billion during the quarter, compared to analysts’ expectations of $8.37 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.23 EPS. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities research analysts predict that Medtronic will post 5.46 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director William R. Jellison acquired 2,500 shares of Medtronic stock in a transaction that occurred on Monday, August 25th. The shares were bought at an average cost of $92.37 per share, with a total value of $230,925.00. Following the transaction, the director directly owned 5,000 shares of the company’s stock, valued at $461,850. This trade represents a 100.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. 0.26% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MDT. Cape Investment Advisory Inc. boosted its holdings in shares of Medtronic by 3.2% in the second quarter. Cape Investment Advisory Inc. now owns 3,605 shares of the medical technology company’s stock valued at $314,000 after acquiring an additional 113 shares during the period. Gilbert & Cook Inc. increased its holdings in shares of Medtronic by 1.9% in the 2nd quarter. Gilbert & Cook Inc. now owns 6,103 shares of the medical technology company’s stock valued at $532,000 after acquiring an additional 114 shares during the period. Red Spruce Capital LLC raised its position in Medtronic by 0.5% in the 2nd quarter. Red Spruce Capital LLC now owns 23,707 shares of the medical technology company’s stock valued at $2,067,000 after purchasing an additional 118 shares during the last quarter. Certior Financial Group LLC boosted its stake in Medtronic by 3.7% during the 1st quarter. Certior Financial Group LLC now owns 3,450 shares of the medical technology company’s stock worth $310,000 after purchasing an additional 122 shares during the period. Finally, Florida Financial Advisors LLC boosted its stake in Medtronic by 4.8% during the 2nd quarter. Florida Financial Advisors LLC now owns 2,683 shares of the medical technology company’s stock worth $234,000 after purchasing an additional 122 shares during the period. Institutional investors own 82.06% of the company’s stock.

Medtronic Company Profile

(Get Free Report)

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

Featured Stories